165 results on '"de Lorenzo, Stefania"'
Search Results
2. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index
3. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab
4. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC
5. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
6. Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
7. A profile of long-term pancreatic cancer survivors
8. Investigating possible relationships between pancreatic cancer and hypothyroidism
9. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
10. Wilson disease, ABCC2 c.3972C > T polymorphism and primary liver cancers: suggestions from a familial cluster
11. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
12. Bone Metastases from Intrahepatic Cholangiocarcinoma Confer Worse Prognosis
13. An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone
14. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
15. Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
16. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma
17. Intestinal Microbiota, Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: The Potential Role of Dysbiosis in the Hepatocarcinogenesis
18. Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept
19. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases
20. Microbiota, NASH, HCC and the potential role of probiotics
21. Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention
22. Small Bowel Adenocarcinoma: From Molecular Insights to Clinical Management
23. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study
24. Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials
25. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma
26. Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib
27. A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index
28. Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development
29. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index
30. Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma
31. Pattern of progression of intrahepatic cholangiocarcinoma: Implications for second‐line clinical trials.
32. Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role
33. Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
34. Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
35. Surveillance improves survival of intrahepatic cholangiocarcinoma arisen in liver cirrhosis
36. Non-alcoholic steatohepatitis is a risk factor for intrahepatic cholangiocarcinoma and affects its long-time outcome: results from a multicenter international case-control study
37. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
38. Intraoperative electrochemotherapy in locally advanced pancreatic cancer: Results and impact on quality of life. a single center experience.
39. Treatment of Combined Hepatocellular and Cholangiocarcinoma
40. Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis
41. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience
42. Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis
43. Surveillance for Hepatocellular Carcinoma Also Improves Survival of Incidentally Detected Intrahepatic Cholangiocarcinoma Arisen in Liver Cirrhosis
44. How to Choose Between Percutaneous Transhepatic and Endoscopic Biliary Drainage in Malignant Obstructive Jaundice: An Updated Systematic Review and Meta-analysis
45. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
46. Adjuvant treatment in biliary tract cancer
47. Role of nonalcoholic steatohepatitis as a risk factor for intrahepatic cholangiocarcinoma and its role in patients’ prognosis: A case-control study.
48. Adjuvant Treatment and Follow-up Strategies
49. Follow-up del cancro del pancreas esocrino
50. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.